VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AAPG
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AAPGAscentage Pharma Group International
$13.01$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
AAPG logo

Ascentage Pharma Group International

AAPG
NASDAQ · Oncology Biotech
$13.01
At close - Nov 18, 4:00 PM EST - USD
Market Cap$1.21B
P/E-6.4x
52W High$33.09
Volume1.77K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

High R&D Burn Amid Rising Leverage and Cash Erosion

Ascentage Pharma's investment thesis is centered on its potential to translate an extensive, R&D-intensive pipeline into commercially viable therapies, as evidenced by high gross margins near 90%.

GrowthMixed
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

AAPG price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

1/12 Beats

EPS beat 1 of last 12 quarters

02

Valuation risk

-116% Peers

P/E is 116% below peer median

03

Market leadership

RS 23 · Lag

Laggard (Underperforming 77% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Nov 18
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue is highly volatile, contracting 43.05% on a TTM basis after a milestone-driven surge, while robust gross margins of 83.9% are entirely consumed by R&D expenses that are 2.27x larger than revenue.

Analyst Consensus+253.5% target
Buy(2 analysts)
2 Buy0 Hold0 Sell

The Bull Case

Upside Catalysts

Strong price target upside

AAPG's current price target is $46.43, with a 12-month projection of $47.88, representing a significant upside potential of +121.1%.

Analyst optimism

Top analysts are forecasting bullish outcomes for AAPG, with some setting a price target as high as $47.88, indicating strong confidence in the stock's growth.

Revenue and earnings growth

AAPG is expected to show robust earnings and revenue growth rates, with forecasts comparing favorably to industry peers.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
AAPG-50.65%
S&P 500 (^GSPC)+6.88%
1-Year Return
AAPG-59.33%
S&P 500 (^GSPC)+10.62%
3-Year Return
AAPG-25.13%
S&P 500 (^GSPC)+59.54%
5-Year Return
AAPG-25.13%
S&P 500 (^GSPC)+54.15%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-6.4x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-6.4x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$4.74-63.6%
Base (Fair)$8.22-46.7%
Bull$9.34-28.2%
$4.74 Bear$8.22 Base$9.34 Bull
Current Market Price: $13.01
Trades at a 58.3% premium to Base DCF ($8.22)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$558M-43.1% YoY
Net income FY25
-$1.21B-198.2% YoY
Free cash flow FY25
-$1.2B-785.9% YoY
Operating margin FY25
-211.1%-173.4 pts YoY
ROIC (FY25)-114.1%
Avg ROIC 5Y-93.4%
ROE (FY25)-150.2%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate1/12 (33%)
Revenue Beat Rate1/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 18, 2026
-$1.30-491.0%
vs -$0.22
$45M-16.4%
vs $54M
Q2 2026
Mar 24, 2026
-$0.65+21.7%
vs -$0.83
$49M+11.5%
vs $44M
Q3 2025
Aug 20, 2025
-$0.96
vs —
$33M
vs —
Q2 2025
Mar 27, 2025
-$1.00-6134.6%
vs $0.02
$21M
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 4, 2026
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026

ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that multiple clinical and preclinical studies have been selected at the 68th American Society of Hematology (ASH) Annual Meeting, involving four of the Company's proprietary innovative drug candidates, namely olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China, lisaftoclax (APG-2575), a potentially best-in-class Bcl-2 inhibitor approved in China, APG-5918, a PRC2/EED inhibitor, and APG-3288, a BTK protein degrader. These new data presentations highlight the Company's global innovation capabilities in hematologic malignancies. Notably, APG-5918 was selected for an oral presentation upon the first disclosure of its clinical data.

GlobeNewsWire·Nov 3, 2026
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London

ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in two upcoming investor conferences in London, United Kingdom.

GlobeNewsWire·Oct 20, 2026
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company's novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Benzinga·Oct 16, 2026
Ascentage Pharma Stock Could More Than Double: Analyst

Ascentage Pharma Group International (NASDAQ:AAPG) stock could see significant upside as the cancer drug developer approaches several major clinical trial results in 2027, according to William Blair.

Filtered for Ascentage Pharma Group InternationalMore Headlines
04

Compare before deciding

Benchmark AAPG against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Ascentage Pharma Group International (AAPG)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AAPG logoAAPGAscentage Pharma Group InternationalCurrent
$13.01$1.21B-6.40-43.05%-216.47%-150.25%—
ABBV logoABBVAbbVie Inc.
$285.96$505.23B48.988.57%15.67%—2.3%
KYMR logoKYMRKymera Therapeutics, Inc.
$121.13$9.96B-34.69-16.72%-341.87%-22.39%—
ARVN logoARVNArvinas, Inc.
$6.77$436.49M-46.56-0.3%-3.45%-2%—
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
GILD logoGILDGilead Sciences, Inc.
$168.98$209.8B-54.722.39%-12.47%-21.84%1.89%

Compare AAPG vs Peers

Ascentage Pharma Group International (AAPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ABBV

Most directly comparable listed peer for AAPG.

Scale Benchmark

vs GILD

Larger-name benchmark to compare AAPG against a more recognizable public peer.

Peer Set

Compare Top 5

vs ABBV, KYMR, ARVN, IMVT

Get notified when AAPG posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AAPG Frequently Asked Questions

Ascentage Pharma Group International (AAPG) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Ascentage Pharma Group International's revenue?

Ascentage Pharma Group International (AAPG) reported $558.5M in revenue in fiscal year 2025. That is 7184% more than the $7.7M of fiscal year 2016.

How fast is Ascentage Pharma Group International growing?

Ascentage Pharma Group International (AAPG) revenue fell by 43.1% in fiscal year 2025, compared with the prior fiscal year.

Is AAPG profitable?

No. Ascentage Pharma Group International (AAPG) reported a net loss of $1.21B in fiscal year 2025.

Dividend & Returns
What is AAPG's return on equity?

Ascentage Pharma Group International (AAPG) had a return on equity (ROE) of -150.2% in fiscal year 2025. A negative ROE means the company lost money over the period.

What is Ascentage Pharma Group International's free cash flow?

Ascentage Pharma Group International (AAPG) had negative free cash flow of $1.20B in fiscal year 2025.

What if you invested $1,000 in AAPG back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →